comScore

Amgen

SYMBOL:AMGN|SECTOR:Health Care|DERIVED:CFD
i
Derived prices are not provided by exchanges. They are derived by market makers in CFD OTC market and hence prices may not be accurate and may differ from the actual market price, meaning prices are indicative only and not appropriate for trading purposes. Therefore Moneycontrol doesn't bear any responsibility for any trading losses you might incur as a result of using this data.
$
2
2
0
0
.
3
3
3
3
2
2
2.58 (1.12%)

As on 05 Oct, 2022 | 01:29 IST

Trade
Day Range
229.80
234.09
LH
52 Week Range
198.64
258.45
LH
Open231.04
Previous Close230.44
Beta-0.07
High234.09
Low229.80
TTM EPS11.80
52 Week High258.45
52 Week Low198.64
TTM PE19.75
Mkt. Cap ($ Billion)124.67
Dividend Yield3.19

Advance Chart

*Delayed by 20 seconds.

MC Technicals

Technical rating
i
This represents current trend.
Click here  for disclaimer.
Trend
Bearish
Moving AveragesBearish
Technical IndicatorsBearish
Moving Averages CrossoversBearish

Pivot levels

TypeR1R2R3PPS1S2S3
Classic230.98 233.56 235.56228.98 226.40 224.40 221.82
Fibonacci230.73 231.81 233.56228.98 227.23 226.15 224.40
Camarilla228.83 229.25 229.67228.98 227.99 227.57 227.15

Note : Support and Resistance level for the day, calculated based on price range of the previous trading day.

Moving Averages
Days
5228.28
10228.59
20235.55
50242.83
100243.58
200237.89

Returns

Price Performance
1 Week2.33%
1 Month
-2.54%
3 Months
-4.21%
YTD3.59%
1 Year9.59%
3 Years20.43%

Peers

NamePrice ($)Change%M.Cap(Billion $)TTM PETTM EPSDY52 wk high/lowTechnical Rating
J&J165.621.48435.4424.116.872.55186.69/155.721.96Neutral
Eli Lilly329.892.59313.5652.636.271.21335.33/226.057.48Very Bullish
AbbVie141.992.65251.0320.007.103.68175.91/106.864.74Bullish
Pfizer44.460.73249.478.705.113.0561.71/40.94-3.05Very Bearish
Merck & Co88.390.96223.9413.546.533.0395.72/71.501.75Neutral

About the company

Amgen Inc. is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. Its marketed products portfolio includes ENBREL, Prolia (denosumab), Neulasta (pegfilgrastim), Otezla, XGEVA, Aranesp (darbepoetin alfa), KYPROLIS, Repatha (evolocumab), Nplate (romiplostim), Vectibix (panitumumab), MVASI (bevacizumab-awwb), Parsabiv (etelcalcetide), EPOGEN (epoetin alfa), KANJINTI (trastuzumab-anns), BLINCYTO (blinatumomab), Aimovig (erenumab-aooe), EVENITY (romosozumab-aqqg), AMGEVITATM (adalimumab), Sensipar/Mimpara (cinacalcet), NEUPOGEN (filgrastim), IMLYGIC (talimogene laherparepvec), Corlanor (ivabradine) and AVSOLA (infliximab-axxq). It focuses on human therapeutics for the treatment of serious illness in the areas of inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology and neuroscience.